Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Intangibles (2022 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Intangibles for 3 consecutive years, with $37.2 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Intangibles changed N/A year-over-year to $37.2 million, compared with a TTM value of $37.2 million through Jun 2025, changed N/A, and an annual FY2024 reading of $36.5 million, up 2.82% over the prior year.
  • Intangibles was $37.2 million for Q2 2025 at Neurocrine Biosciences, up from $36.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $37.2 million in Q2 2025 and bottomed at $34.9 million in Q3 2023.
  • Average Intangibles over 3 years is $36.2 million, with a median of $36.4 million recorded in 2024.
  • Peak annual rise in Intangibles hit 2.82% in 2024, while the deepest fall reached 2.82% in 2024.
  • Year by year, Intangibles stood at $35.5 million in 2023, then rose by 2.82% to $36.5 million in 2024, then grew by 1.92% to $37.2 million in 2025.
  • Business Quant data shows Intangibles for NBIX at $37.2 million in Q2 2025, $36.4 million in Q1 2025, and $36.5 million in Q4 2024.